Testing effectiveness (Phase 2)UnknownNCT03226301
What this trial is testing
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations
Who this might be right for
Chronic Lymphocytic Leukemia in RelapseChronic Lymphocytic Leukemia in Remission
Stichting Hemato-Oncologie voor Volwassenen Nederland 230